# Developmental Funds

> **NIH NIH P30** · WISTAR INSTITUTE · 2022 · $399,936

## Abstract

PROJECT SUMMARY – DEVELOPMENTAL FUNDS
Developmental Funds have played a critical role in supporting transformative advances of the Cancer Center
during the last five years. Judiciously allocated and thoroughly monitored, Developmental Funds have
significantly advanced the mission of the Cancer Center in three strategic areas: (i) thematic faculty recruitment
to create “critical mass” in selected research areas; (ii) creation of a Cancer Center infrastructure to support
human subject research; and (iii) expansion of the inter-institutional partnership with the Helen F Graham
Cancer Center (HFGCC) for translational and patient-focused cancer research. With the support of
Developmental Funds, the Cancer Center recruited three new faculty members during the last Cancer Center
Support Grant (CCSG) budget cycle, adding research depth and collaborative opportunities in the areas of
functional genomics, cancer metabolism and mechanisms of metastasis; supported the full development and
launch of the Cancer Center’s Biomedical Research Support Shared Resource to manage all aspects of
patient-related cancer research, HIPAA-compliant regulatory requirements and tracking of human samples;
and expanded the inter-institutional collaboration with the HFGCC, enhancing tissue procurement, secure data
transfer and a new, collaborative pilot project program. Presented at the 2013 CCSG renewal as a developing
initiative, the Wistar-HFGCC partnership is the first in the nation to bring together two NCI-sponsored
programs: an NCI-designated “basic” Cancer Center (Wistar) and a member of the NCI Community Oncology
Research Program (NCORP, HFGCC). The allocation of Developmental Funds enabled the success of this
fully collaborative model of translational cancer research, and in the last five years, Wistar Cancer Center
members accessed over 1,800 clinically-annotated tissue samples from the HFGCC, published 15 impactful
articles in collaboration with HFGCC clinicians, added gene-editing technologies provided by the HFGCC Gene
Editing Institute to the Molecular Screening Shared Resource, opened an investigator-initiated phase I clinical
trial at the HFGCC based on Wistar discoveries (NCT02259231) and obtained over $17 million in cancer-
related federal funding, including a collaborative, Wistar-HFGCC Program Project grant (P01 CA140043). This
trajectory will continue during the next CCSG budget cycle, as strategically planned allocation of
Developmental Funds will support (i) faculty recruitment in the thematic areas of functional genomics and
tumor immunology; (ii) synergistic collaborative alignment between the Cancer Center and the Vaccine and
Immunotherapy Center (VIC); and (iii) further expansion of Wistar-HFGCC collaborations in patient-focused
cancer research.

## Key facts

- **NIH application ID:** 10360646
- **Project number:** 5P30CA010815-53
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Dario C Altieri
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $399,936
- **Award type:** 5
- **Project period:** 1997-04-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10360646

## Citation

> US National Institutes of Health, RePORTER application 10360646, Developmental Funds (5P30CA010815-53). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10360646. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*